The advent of next-generation sequencing (NGS) revolutionized advanced cancer care, but its full-scale potential is only beginning to unfurl as it makes a powerful shift to the frontline, particularly in lung cancer. This is where the transformative ProMPT tool comes into play, enhancing NGS reports and harnessing the power of vast genomic data to shape personalized patient care decisions. It is a shining testament to the potency of gene signatures in shaping the future of treatment strategies.
The expanding availability of NGS to all patients, not merely those battling late-stage disease, is a crucial juncture in optimizing treatment outcomes. The abundant genomic testing data harvested over the years is a treasure trove, offering a deeper comprehension of how gene signatures can affect treatment intricacies across diverse cancer types. This paradigm shift towards incorporating NGS at the heart of cancer care is a giant leap forward in precision medicine, laying the foundation for more targeted and potent treatment strategies.
Oncology treatments have evolved into intricate systems, increasingly leaning on biomarker-driven therapies. This evolution has created a challenging landscape for clinicians, making it difficult for them to stay updated on emerging methodologies. Furthermore, extracting and understanding genomic data from NGS reports can often be a conundrum, as it’s not conveniently searchable.
In a recent discussion with Targeted Oncology™, Neha Jain, PhD, a Senior Director of Precision Medicine at OneOncology in Nashville, Tennessee, shed light on the rollout of the Provider Messaging for Precision Therapies (ProMPT). This groundbreaking tool is designed to support clinical decision-making by enabling oncologists to navigate existing patient testing reports and results, explore corresponding FDA approved precision therapy options, receive updates for additional available testing, and obtain support from the OneOncology Precision Medicine team.
ProMPT operates as a Google Chrome extension that leverages raw sequencing data sourced from a tissue or blood sample that the oncologist submits for NGS. While the final output usually takes the form of a PDF report, a JSON file—a malleable, queryable format—is first generated, serving as a critical component for ProMPT. Given that NGS is performed by multiple vendors, resulting in varied JSON files, ProMPT harmonizes the data and links it to the patient.
This shift in leveraging NGS and tools like ProMPT right from the get-go of cancer care is a testament to the opportunities that lie in precision medicine. By translating the genomic dialect of cancer into actionable therapeutic strategies, we’re opening new avenues for targeted treatment, ushering in an era of hope and healing for patients battling the scourge of cancer.
Read more from targetedonc.com
